API | pralsetinib

pralsetinib Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Breakthrough Therapy ^FDA Accelerated Approval ^FDA Priority Review ^FDA

Active Ingredient History

NOW

Now

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Drug Pricing (per unit)

United States

$112.4422 - $154.7837

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (3)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (18)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (18)

Adenocarcinoma (Phase 3)

Bronchial Diseases (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Bronchogenic (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Head and Neck Neoplasms (Phase 3)

Lung Diseases (Phase 3)

Lung Neoplasms (Phase 3)

Neoplasms (Phase 3)

Neoplasms by Histologic Type (Phase 3)

Neoplasms by Site (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Neoplasms, Nerve Tissue (Phase 3)

Respiratory Tract Diseases (Phase 3)

Respiratory Tract Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 3)

Thoracic Neoplasms (Phase 3)

Thyroid Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue